• LAST PRICE
    4.2500
  • TODAY'S CHANGE (%)
    Trending Up0.1900 (4.6798%)
  • Bid / Lots
    4.2500/ 3
  • Ask / Lots
    4.2700/ 5
  • Open / Previous Close
    4.2800 / 4.0600
  • Day Range
    Low 4.1100
    High 4.4300
  • 52 Week Range
    Low 2.8300
    High 9.0100
  • Volume
    490,732
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 4.06
TimeVolumeABEO
09:32 ET174444.24
09:34 ET194704.35
09:36 ET99194.39
09:38 ET30034.38
09:39 ET89064.32
09:41 ET16004.27
09:43 ET31364.19
09:45 ET28004.21
09:48 ET53934.2049
09:50 ET29054.22
09:52 ET2004.185
09:54 ET16004.2
09:56 ET10004.2105
09:57 ET24164.23
09:59 ET11004.21
10:03 ET26004.205
10:06 ET269994.15
10:08 ET80364.17
10:10 ET6004.13
10:12 ET5004.12
10:14 ET20624.11
10:15 ET18744.14
10:17 ET57004.145
10:19 ET10004.15
10:21 ET6004.17
10:24 ET1004.17
10:26 ET7004.17
10:28 ET7804.185
10:30 ET54004.19
10:32 ET2004.21
10:33 ET1004.21
10:35 ET2004.21
10:37 ET14874.22
10:46 ET79034.24
10:48 ET8004.22
10:51 ET13794.23
10:53 ET46004.24
10:55 ET20004.2201
10:57 ET48174.2505
11:00 ET9004.28
11:02 ET2004.26
11:04 ET1004.265
11:06 ET15194.245
11:09 ET6004.255
11:11 ET5004.25
11:13 ET9204.255
11:15 ET6004.27
11:18 ET35004.255
11:20 ET3004.24
11:22 ET12004.255
11:26 ET28504.31
11:27 ET15004.303
11:29 ET2504.3
11:31 ET11234.33
11:36 ET8004.31
11:38 ET1004.305
11:40 ET6004.28
11:45 ET7004.306
11:47 ET21534.2978
11:49 ET586764.36
11:51 ET6004.36
11:54 ET189324.31
11:56 ET20004.31
11:58 ET72484.3
12:00 ET1004.295
12:02 ET70004.3
12:05 ET8074.3
12:07 ET98134.3
12:09 ET2004.315
12:12 ET9004.32
12:14 ET10004.32
12:16 ET8004.32
12:20 ET6004.32
12:21 ET2004.32
12:23 ET220494.27
12:25 ET24804.2665
12:27 ET2004.26
12:30 ET56004.25
12:32 ET7004.24
12:34 ET11524.24
12:36 ET12594.22
12:38 ET90124.23
12:39 ET10004.23
12:45 ET11004.23
12:48 ET73224.24
12:52 ET3004.24
12:54 ET131484.24
12:57 ET14004.258
12:59 ET27004.245
01:01 ET1004.245
01:03 ET10504.22
01:06 ET15604.2201
01:08 ET1004.22
01:12 ET18004.23
01:17 ET58614.241
01:21 ET2004.2453
01:24 ET4004.255
01:26 ET12004.26
01:28 ET3004.28
01:30 ET2004.26
01:32 ET5004.26
01:33 ET3004.25
01:35 ET4004.27
01:39 ET7004.255
01:42 ET13004.24
01:46 ET2004.245
01:48 ET18004.225
01:50 ET28804.225
01:53 ET10004.23
01:57 ET10004.22
02:00 ET1004.23
02:04 ET1004.215
02:08 ET5004.215
02:09 ET6754.21
02:11 ET3754.21
02:13 ET2004.21
02:15 ET42534.22
02:22 ET1004.235
02:24 ET11004.22
02:26 ET1004.235
02:27 ET2004.22
02:29 ET31214.22
02:31 ET9004.21
02:33 ET24744.2001
02:36 ET3004.21
02:38 ET6004.21
02:42 ET10004.22
02:44 ET13004.225
02:45 ET17944.22
02:47 ET13004.22
02:49 ET1664.22
02:51 ET1004.22
02:54 ET1004.225
02:56 ET30154.23
02:58 ET13004.24
03:00 ET11004.24
03:02 ET47284.22
03:03 ET230004.25
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesABEO
Abeona Therapeutics Inc
167.2M
-1.3x
---
United StatesADVM
Adverum Biotechnologies Inc
166.5M
-0.8x
---
United StatesBLUE
bluebird bio Inc
171.6M
-1.2x
---
United StatesSGMT
Sagimet Biosciences Inc
174.6M
-4.3x
---
United StatesOTLK
Outlook Therapeutics Inc
166.9M
-0.6x
---
United StatesATOS
Atossa Therapeutics Inc
166.0M
-5.6x
---
As of 2024-05-30

Company Information

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Contact Information

Headquarters
6555 CARNEGIE AVE, 4TH FLOORCLEVELAND, OH, United States 44103
Phone
646-813-4701
Fax
302-655-5049

Executives

Chairman of the Board
Michael Amoroso
President, Chief Executive Officer, Director
Vishwas Seshadri
Chief Financial Officer
Joseph Vazzano
General Counsel
Brendan O Malley
Independent Director
Leila Alland

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$167.2M
Revenue (TTM)
$3.5M
Shares Outstanding
41.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.50
EPS
$-3.20
Book Value
$0.56
P/E Ratio
-1.3x
Price/Sales (TTM)
47.8
Price/Cash Flow (TTM)
---
Operating Margin
-1,412.20%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.